Companies
Emergent BioSolutions
supplies anthrax vaccine and smallpox medical countermeasures under direct government delivery contracts, including a contract with the US Department of War and international government partners.
- Country
- United States
- Ticker
- NYSE:EBS
NYSE: EBS
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| policy-institutions | ✓ | ✓ | ✓ |
Regulatorsfdaepa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $743 million for 2025 | emergentbiosolutions.com |
| Headcount | 850 employees | emergentbiosolutions.com |
| Funding | $52.7 million contract modification (June 2026) for ACAM2000 | investors.emergentbiosolutions.com · synapse.patsnap.com · fiercepharma.com · sec.gov |
| Funding | $30 million contract modification (September 2025) for CYFENDUS | investors.emergentbiosolutions.com · synapse.patsnap.com · fiercepharma.com · sec.gov |
| Funding | $54 million contract award (March 2026) for CNJ-016 | investors.emergentbiosolutions.com |
| Funding | $235.8 million five-year contract (2024) for BioThrax | fiercepharma.com |
| Production site | Winnipeg, Canada | emergentbiosolutions.com · sec.gov |
| Production site | Lansing, Michigan | emergentbiosolutions.com · sec.gov |
| Production site | Baltimore, Maryland (Bayview and Camden) | investors.emergentbiosolutions.com · emergentbiosolutions.com |
| Production site | Canton, Massachusetts | emergentbiosolutions.com |
| Production site | Hattiesburg, Mississippi | emergentbiosolutions.com |
| Production site | Rockville, Maryland | emergentbiosolutions.com |
| Certification | No Action Indicated (NAI) status for Baltimore Bayview facility (March 2024) | investors.emergentbiosolutions.com |
| Certification | Voluntary Action Indicated (VAI) status for Camden facility (October 2023) | sec.gov |
| Regulatory approval | FDA approval for CYFENDUS (July 2023) | investors.emergentbiosolutions.com · sec.gov |
| Regulatory approval | FDA sBLA approval for raxibacumab manufacturing in Winnipeg (December 2025) | sec.gov |
Independent sources: fiercepharma.com · sec.gov · synapse.patsnap.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Defense bioeconomy | policy-institutions | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.